• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


Prices delayed by at least 15 minutes | Print

Live UK pricing:

Faron Pharmaceuticals Oy (FARN)

ORD NPV (DI)
Sell: 28.00p|Buy: 32.00p|Change: 1.90 (-6.33%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPPand can be used with Dividend reinvestment

This investment is listed on the Alternative Investment Market (AIM). Investments on this market can be higher risk and have lower liquidity, meaning they can be harder to buy or sell, and their prices may be more volatile. Before investing, make sure you understand the risks of investing.

Company profile

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company. The company has one operating and reportable segment. The Group has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Faron is a late clinical stage drug discovery and development Group. The company includes Bexmarilimab in its pipeline. Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and improve clinical outcomes by targeting myeloid cell function in the microenvironment and igniting the immune system against cancer.

Address

Joukahaisenkatu 6, Intelligate
Turku
FIN
FI-20520

Telephone

+358 24695151

Website

https://www.faron.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Faron Pharmaceuticals Oy Second Quarter Earnings Conference Call for 20272027-08-26T08:00:00
Faron Pharmaceuticals Oy Second Quarter Earnings Results for 20272027-08-26T00:00:00
Faron Pharmaceuticals Oy Annual General Meeting for 20262027-05-04T10:00:00
Faron Pharmaceuticals Oy Fourth Quarter Earnings Conference Call for 20262027-03-04T09:00:00
Faron Pharmaceuticals Oy Fourth Quarter Earnings Results for 20262027-03-04T00:00:00
Faron Pharmaceuticals Oy Annual Report for 20262027-03-04T00:00:00

Previous key dates

NameKey Date
Faron Pharmaceuticals Oy Second Quarter Earnings Conference Call for 20262026-08-26T08:00:00
Faron Pharmaceuticals Oy Second Quarter Earnings Result for 20262026-08-26T00:00:00
EHA 20262026-05-12T18:45:00
Faron Pharmaceuticals Oy Annual General Meeting for 20252026-05-04T10:00:00
Faron Pharmaceuticals Oy Fourth Quarter Earnings Conference Call for 20252026-03-04T09:00:00
Faron Pharmaceuticals Oy Fourth Quarter Earnings Result for 20252026-03-04T00:00:00
Faron Pharmaceuticals Oy Annual Report for 20252026-03-04T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.